1. Home
  2. STTK vs ATLO Comparison

STTK vs ATLO Comparison

Compare STTK & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • ATLO
  • Stock Information
  • Founded
  • STTK 2016
  • ATLO 1903
  • Country
  • STTK United States
  • ATLO United States
  • Employees
  • STTK N/A
  • ATLO N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • ATLO Major Banks
  • Sector
  • STTK Health Care
  • ATLO Finance
  • Exchange
  • STTK Nasdaq
  • ATLO Nasdaq
  • Market Cap
  • STTK 83.8M
  • ATLO 177.0M
  • IPO Year
  • STTK 2020
  • ATLO N/A
  • Fundamental
  • Price
  • STTK $2.14
  • ATLO $20.42
  • Analyst Decision
  • STTK Hold
  • ATLO
  • Analyst Count
  • STTK 6
  • ATLO 0
  • Target Price
  • STTK $2.67
  • ATLO N/A
  • AVG Volume (30 Days)
  • STTK 1.5M
  • ATLO 11.1K
  • Earning Date
  • STTK 11-13-2025
  • ATLO 11-07-2025
  • Dividend Yield
  • STTK N/A
  • ATLO 3.92%
  • EPS Growth
  • STTK N/A
  • ATLO 43.95
  • EPS
  • STTK N/A
  • ATLO 1.53
  • Revenue
  • STTK $2,997,000.00
  • ATLO $57,731,000.00
  • Revenue This Year
  • STTK N/A
  • ATLO N/A
  • Revenue Next Year
  • STTK N/A
  • ATLO N/A
  • P/E Ratio
  • STTK N/A
  • ATLO $13.47
  • Revenue Growth
  • STTK N/A
  • ATLO 12.59
  • 52 Week Low
  • STTK $0.69
  • ATLO $15.69
  • 52 Week High
  • STTK $3.95
  • ATLO $20.75
  • Technical
  • Relative Strength Index (RSI)
  • STTK 58.93
  • ATLO 63.31
  • Support Level
  • STTK N/A
  • ATLO $20.00
  • Resistance Level
  • STTK $2.01
  • ATLO $20.72
  • Average True Range (ATR)
  • STTK 0.21
  • ATLO 0.35
  • MACD
  • STTK 0.01
  • ATLO 0.01
  • Stochastic Oscillator
  • STTK 99.53
  • ATLO 71.30

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About ATLO Ames National Corporation

Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.

Share on Social Networks: